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Summary. Background: Neuroendocrine differentiation 
in prostatic carcinoma has been related to regulation of 
proliferation and metastatic potential and correlated with 
prognosis. More than 80% of prostate carcinomas 
initially respond to androgen ablation, but most relapse, 
due to the heterogeneous presence of androgen- 
dependent and independent clones. The pathways of 
cellular proliferation and apoptosis are inexorabily 
linked to minimize the ocurrence of neoplasia, and 
disfunction of apoptosis is proposed as a pathogenic 
process in malignant tumors. Androgen-dependent 
prostatic cancer cells undergo apoptosis after androgen 
deprivation, but not androgen-independent ones due to a 
defect in the initiation step. Anyway, they retain the 
basic cellular machinery to undergo apoptosis. We 
suggest a possible role of neuroendocrine differentiation 
in the onset and regulation of apoptosis in prostatic 
neoplasia. Methods: LNCaP, PC-3 and DU 145 prostatic 
cancer cell lines were induced to undergo apoptosis after 
treatment with etoposide alone or plus androgen 
ablation. We tested the role of neuropeptides bombesin 
and calcitonin at modulating etoposide induced 
apoptosis. Results: Etoposide-induced apoptosis in all 
cancer cell lines was achieved. In LNCaP androgen 
ablation was also required. Apoptosis is prevented in all 
three lines when bombesin was added. Calcitonin 
addition prevents apoptosis in PC-3, LNCaP and in an 
etoposide dose-dependent way in DU 145. Conclusion: 
Neuropeptides bombesin and calcitonin can modulate 
the apoptotic response of prostate cancer cells by 
inducing resistance to etoposide-induced apoptosis, 
suggesting that neuropeptides can be used as a target of 
therapeutical approach in prostatic carcinoma. 
Key words: Apoptosis, Modulation, Neuroendocrine 
peptides, Prostate carcinoma, Etoposide 
Offprint requests to: Dra. M. Salido, Department of Cellular 
Biology.,School of Medicine, University of CAdiz, Plaza Fragela sln, 
11003 CBdiz, Spain. e-mail: mercedes.salido@uca.es 
Introduction 
Over the last decade, prostate cancer has become the 
most commonly diagnosed cancer in men. Of all 
cancers, the incidence of prostate cancer increases most 
rapidly with age, with an average age at diagnosis of 70 
years, with 80% of cases being diagnosed in men over 
65. Due to detection at an earlier age, there has also been 
a rapid increase in men diagnosed under the age of 65. 
Mortality from prostate cancer has increased at a slower 
rate but overall has doubled in the last 5 0  years. 
Although typically diagnosed in men over the age of 65, 
the impact of the disease is still significant in that the 
average lifespan of a man who dies from prostate cancer 
is reduced by 9 to 1 0  years (Denmeade and Isaacs, 
1996). 
Growth of a cancer is determined by the relationship 
beween the rate of cell proliferation and the rate of cell 
death. Only when the rate of cell proliferation is greater 
than cell death does the tumor growth continue. If the 
rate of cell proliferation is lower than the rate of cell 
death, then regression of the cancer ocurrs (Gerschenson 
and Rotello, 1992; Payne et al., 1995; Denmeade and 
Isaacs, 1996). 
Metastatic prostate cancers, like the normal prostates 
from which they arise, are sensitive to androgenic 
stimulation of their growth, due to the presence of 
androgen-dependent prostatic cancer cells. These cells 
are androgen-dependent since androgens stimulate their 
daily rate of cell proliferation while inhibiting their rate 
of death. In contrast, following androgen ablation, 
androgen-dependent prostatic cancer cel ls  s top 
proliferating and activate a cellular suicide pathway 
termed programmed cell death or apoptosis. This 
activation results in the elimination of these androgen- 
dependent prostatic cancer cells from the patient. Due to 
this elimination, 80-90% of all men with metastatic 
prostate cancer treated with androgen ablation therapy 
have an initial positive response. All of these patients 
relapse eventually to a state unresponsive to further 
antiandrogen therapy, no matter how completely given. 
This is due to the heterogeneous presence of androgen- 









